Reading a Peptide HPLC Trace — A 5-Minute Field Guide for Bench Scientists. Read our briefing →
Reading a peptide HPLC trace — a field guide. Read →
On reading HPLC traces. Read →
Co-characterized amylin + GLP-1 reference pairing
Overview
CagriSema is the combination of the long-acting amylin analog Cagrilintide with the GLP-1 receptor agonist Semaglutide — two molecules acting through distinct receptor families (the amylin / calcitonin-receptor axis and the GLP-1 receptor) that the metabolic-research literature studies together under the CagriSema designation. As an investigational combination it is not an approved finished drug; the material referenced here is a research reagent only, framed as a reference pairing rather than for any weight-management outcome. Lyochem's methodology preference for a two-component system is to characterize each component on its own analytical packet rather than ship a pre-mixed blend whose per-component data is obscured. Cagrilintide and Semaglutide are each supplied as separately characterized lots — RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer per lot — so a lab can confirm identity and purity of each before preparing the combination in-protocol at its own ratio. Because the components carry individual CAS numbers rather than a single registered identifier for the combination, the per-lot COA is the operative identity document; confirm the API of each component by COA / label before use. Fills run mg-scale; this is reference-grade research material, distinct from compounding-scale API supply.
Applications & buyer fit
GLP-1 and metabolic-peptide buyers run incretin-pathway, body-composition, glucose-regulation, and energy-expenditure studies. Because the receptor pharmacology is sequence-sensitive, qualifying a new source means confirming identity within 0.5 Da of theoretical by ESI-MS, sequence verification by tandem MS on the first lot, and lot-to-lot consistency for reproducible metabolic research. Lyochem supplies this class reference-grade and mg-scale — distinct from compounding-grade (g/kg) API supply.
Academic Laboratories
Universities, medical schools, and government research institutes qualifying a reference standard for a method-development or in vivo workflow.
Biotech R&D Groups
Preclinical biotech and pharmaceutical discovery teams sourcing characterized peptides for receptor-pharmacology, screening, and method-development campaigns.
Every release ships with its own batch-specific CoA — identity, purity, and the analytical scope agreed at quote stage, tied to the exact lot you receive.
Review a representative batch CoA before you order, so you can confirm the packet matches what your method or sponsor audit needs.
Supplied strictly as a research reagent to research institutions — not a finished dosage form and not for human administration. Buyer qualification runs at the inquiry stage.
Specifications
Documentation available on request
Regulatory note
Investigational combination; not approved as a finished drug at the time of writing. Components carry individual CAS numbers — confirm each component's API identity by batch COA / label before use. Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations — not a finished dosage form and not labelled for human administration. Buyers are responsible for institutional biosafety review and import-eligibility verification.
Frequently asked questions
No. Lyochem supplies Cagrilintide and Semaglutide as separate characterized lots, each with its own analytical packet, rather than a pre-mixed vial. This lets a lab confirm the identity and purity of each component independently before preparing the combination in-protocol — the methodologically cleaner approach, because a pre-mixed product obscures the per-component analytical data a citable methods section needs.
CagriSema is a combination of two distinct molecules, each with its own CAS Registry Number, rather than a single chemical entity, so there is no single registered identifier for the pairing. Identity is established at the component level on each lot COA (ESI-MS against the theoretical mass for each supplied form); buyers should confirm the API of each component by COA or label rather than relying on the combination name.
Each component is independently characterized — RP-HPLC purity, ESI-MS identity, LC-MS/MS sequence verification on request, counter-ion content, and water content by Karl Fischer — so the pairing is defined by two citable per-lot data packets rather than a single blended COA. A lab reconstitutes and combines the two at its chosen ratio in-protocol, with each component's identity already confirmed against its own standard.
Related peptides
Long-acting amylin analog · metabolic research peptide
GLP-1 receptor agonist · 31-mer metabolic research peptide
GIP / GLP-1 dual receptor agonist · 39-mer metabolic research peptide